Abstract Prostate Cancer (PCa) is the second leading cause of cancer-related death in men.
Adenocarcinoma of the prostate is primarily composed of Androgen Receptor-positive (AR+) …

Prostate cancer (PCa), one of the most commonly diagnosed cancers worldwide, still
presents important unmet clinical needs concerning treatment. In the last years, the …

Background Immunotherapeutic regulation of the tumor microenvironment in prostate cancer
patients is not understood. Most antibody immunotherapies have not succeeded in prostate …

Prostate cancer (PCa) is a common malignant disease among men and biochemical
recurrence (BCR) is considered to be a decisive risk factor for clinical recurrence and PCa …

Metastatic bone disease is a common and devastating complication to cancer, confounding
treatments and recovery efforts and presenting a significant barrier to de-escalating the …

Current outcome prediction markers for localized prostate cancer (PCa) are insufficient. The
impact of the lipid-modifying Sphingomyelin Phosphodiesterase Acid Like 3B (SMPDL3B) in …

高危前列腺癌(HRPCa) 是一种异质性疾病, 易出现隐匿性转移, 治疗后易早期复发,
局部治疗(根治手术或放疗) 后生化复发率高达55%~ 70%. 前列腺癌新辅助治疗是指患者在接受 …

Рак предстательной железы (РПЖ) остается одной из наиболее актуальных проблем
современной онкоурологии, что обусловлено его высокой распространенностью и …

The way medicines are developed, regulated and priced determines how quickly patients
have access to safe, effective and affordable medicines. The associated policies, processes …

Drug repurposing represents the fastest and most economical way to deliver therapeutic
innovations to patients. By eliminating the process of new molecule development and the …